Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EU6F | ISIN: DK0062498333 | Ticker-Symbol: NOV
Tradegate
22.01.25
10:51 Uhr
78,53 Euro
+0,90
+1,16 %
1-Jahres-Chart
NOVO NORDISK A/S Chart 1 Jahr
5-Tage-Chart
NOVO NORDISK A/S 5-Tage-Chart
RealtimeGeldBriefZeit
78,4978,5210:51
78,4978,5110:51
PR Newswire
493 Leser
Artikel bewerten:
(2)

Novo Nordisk Foundation grants €134.1 million to establish the Biotechnology Research Institute for the Green Transition (BRIGHT) in Denmark

Finanznachrichten News

BRIGHT aims to accelerate the development of biosolutions that can strengthen the bio-based economy

COPENHAGEN, Denmark, Dec. 18, 2024 /PRNewswire/ -- Our daily lives are full of products and processes based on fossil materials, or created using fossil energy sources such as oil and gas. To make significant progress in the green transition, we need to become much better at harnessing the power of bioproduction - biologically based production solutions that can replace fossil energy sources and materials. These are also known as biosolutions.

This is the aim of the new initiative at the Technical University of Denmark (DTU): Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition (BRIGHT). The new initiative aims to create knowledge and solutions that can be transformed into efficient bioproduction, making a significant contribution to the green transition of society.

"BRIGHT will be a gathering point for academic and industrial partners working together to harness the power of bioproduction. It will help us develop scalable solutions that can significantly reduce our greenhouse gas emissions and expand Denmark's position within bio-based industry," says Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation, which supports the new initiative with a grant of up to DKK 1.05 billion over the next seven years.

Utilizing the power of bioproduction
BRIGHT will focus on three main areas:

  • Sustainable materials
  • Microbial foods
  • Microorganisms for net-zero agriculture

The goal is to develop and scale innovative biosolutions within each of these areas, ultimately creating sustainable and competitive alternatives to fossil-based products and processes that can make significant contributions to reducing global greenhouse gas emissions.

At BRIGHT, researchers across DTU will collaborate with research colleagues from other universities in Denmark and internationally, as well as with industry. A unique feature of BRIGHT will be the introduction of a so-called mission enabler, aimed at promoting promising projects and testing their scalability.

DTU is a leader in biotechnology research in Denmark and is steadily increasing its international position. Therefore, DTU is an obvious hub for the further development and scaling of bioproduction in Denmark, which BRIGHT can become.

"BRIGHT will further strengthen DTU's position in fundamental biotechnology and enable even better collaboration between strong competencies across the university and with external partners, particularly companies. At the same time, we will have an even better foundation for educating highly specialized engineers necessary to drive the bioeconomy forward," says Anders Bjarklev, President of DTU.

Targeted at developing scalable solutions
DTU is currently home to the Novo Nordisk Foundation Center for Biosustainability, which has contributed globally with technologies for developing microbial cell factories - an essential part of bio-based production. BRIGHT will build on these competencies, supplemented by other DTU strongholds. As the grant for BRIGHT is phased in, activities at the Novo Nordisk Foundation Center for Biosustainability will transition to BRIGHT or be phased out.

"The Novo Nordisk Foundation Center for Biosustainability has excelled in many parameters and has helped consolidate DTU as a leader in biotechnology research and innovation. I particularly commend the innovation culture and the centre's outstanding ability to generate spinout companies. With the grant for BRIGHT, the Novo Nordisk Foundation, in collaboration with DTU, aims to become even more focused on developing scalable solutions and accelerating their commercialization in collaboration with industry," explains Mads Krogsgaard Thomsen.

BRIGHT will start its activities in 2025.

About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people's health and the sustainability of society and the planet. The Foundation's mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.

Cision View original content:https://www.prnewswire.co.uk/news-releases/novo-nordisk-foundation-grants-134-1-million-to-establish-the-biotechnology-research-institute-for-the-green-transition-bright-in-denmark-302334103.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.